search
Back to results

Treatment of Thoracic Outlet Syndrome (TOS) With Botox

Primary Purpose

Thoracic Outlet Syndrome

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Botulinum Toxin Type A injection (BOTOX)
Botulinum Toxin Type A injection (BOTOX)
Sponsored by
University of British Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Thoracic Outlet Syndrome focused on measuring Thoracic Outlet Syndrome (TOS), Botulinum Toxin, Botox, Pain

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age at least 19 years
  • Medically stable
  • Able to give informed consent
  • Meets criteria for clinical diagnosis of TOS
  • Symptoms of TOS present for at least six months
  • Have had EMG studies and a CT or MRI scan of the cervical spine

Exclusion Criteria:

  • Prior treatment with BTX-A
  • Allergy to BTX-A
  • History of botulinum toxicity
  • Prior scalenectomy
  • Surgery for TOS planned within six months
  • Use of blood thinners, i.e., warfarin; unfractionated or low molecular weight heparin
  • History of Myasthenia Gravis, Eaton-Lambert Syndrome or Shy-Drager Syndrome
  • Unable to complete follow-up assessments at 6 weeks, 3 months and 6 months
  • Any abnormalities on EMG, CT or MRI studies suggesting an alternate diagnosis
  • Pregnancy or planned pregnancy within six months

Sites / Locations

  • GF Strong Rehabilitation Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1

2

Arm Description

To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.

To assess the effect of BOTOX injection on numbness and tingling and quality of life.

Outcomes

Primary Outcome Measures

Pain as measured on Visual Analog Scale (VAS) at 6 weeks, 3 months and 6 months post-intervention

Secondary Outcome Measures

Paresthesias as measured on VAS
Function as measured with Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, SF-36, number of days lost from work

Full Information

First Posted
March 7, 2007
Last Updated
February 9, 2011
Sponsor
University of British Columbia
Collaborators
Allergan
search

1. Study Identification

Unique Protocol Identification Number
NCT00444886
Brief Title
Treatment of Thoracic Outlet Syndrome (TOS) With Botox
Official Title
Treatment of Thoracic Outlet Syndrome With Botulinum Toxin Injection: A Double-Blind, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
February 2011 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of British Columbia
Collaborators
Allergan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is: To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS. To assess the effect of BOTOX injection on numbness and tingling and quality of life.
Detailed Description
Background: Thoracic Outlet Syndrome (TOS) is a symptom complex consisting of pain, paresthesias and often functional impairment caused by compression of the neurovascular supply to the upper limb. Impingement may occur at the interscalene triangle, and both anesthetic blockade and chemodenervation of the scalene muscles have been shown to temporarily improve symptoms of TOS in non-randomized controlled trials. Objective: To assess the effect of Botulinum Toxin Type A (BTX-A) injections into the scalene muscles on pain, paresthesias and function in subjects with TOS. Hypothesis: BTX-A injected into the anterior and middle scalene muscles will reduce the irritation on the neurovascular structures at the interscalene triangle in subjects with TOS. This will lead to reductions in pain and paresthesias, and improvements in function when compared with injection of placebo. Intervention: Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thoracic Outlet Syndrome
Keywords
Thoracic Outlet Syndrome (TOS), Botulinum Toxin, Botox, Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
Arm Title
2
Arm Type
Active Comparator
Arm Description
To assess the effect of BOTOX injection on numbness and tingling and quality of life.
Intervention Type
Drug
Intervention Name(s)
Botulinum Toxin Type A injection (BOTOX)
Intervention Description
Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
Intervention Type
Drug
Intervention Name(s)
Botulinum Toxin Type A injection (BOTOX)
Intervention Description
Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
Primary Outcome Measure Information:
Title
Pain as measured on Visual Analog Scale (VAS) at 6 weeks, 3 months and 6 months post-intervention
Time Frame
6 monhts
Secondary Outcome Measure Information:
Title
Paresthesias as measured on VAS
Time Frame
6 months
Title
Function as measured with Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, SF-36, number of days lost from work
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age at least 19 years Medically stable Able to give informed consent Meets criteria for clinical diagnosis of TOS Symptoms of TOS present for at least six months Have had EMG studies and a CT or MRI scan of the cervical spine Exclusion Criteria: Prior treatment with BTX-A Allergy to BTX-A History of botulinum toxicity Prior scalenectomy Surgery for TOS planned within six months Use of blood thinners, i.e., warfarin; unfractionated or low molecular weight heparin History of Myasthenia Gravis, Eaton-Lambert Syndrome or Shy-Drager Syndrome Unable to complete follow-up assessments at 6 weeks, 3 months and 6 months Any abnormalities on EMG, CT or MRI studies suggesting an alternate diagnosis Pregnancy or planned pregnancy within six months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Travlos, MD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
GF Strong Rehabilitation Centre
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 2G9
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Treatment of Thoracic Outlet Syndrome (TOS) With Botox

We'll reach out to this number within 24 hrs